Skin cancer survivors test cream combo to stop new tumors

NCT ID NCT04091022

Completed Prevention Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a combination of two FDA-approved creams (diclofenac and DFMO) can prevent new non-melanoma skin cancers in people who have already had them. 64 participants applied the creams or a placebo to their arms for 9 months. The goal was to see if the treatment reduced the number of precancerous spots and new skin cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: topical diclofenac 3% cream and topical eflornithine (DFMO) 13.9% cream
What this could lead to: If successful, this combination cream could offer a new way to prevent non-melanoma skin cancers from forming in people who have already had them.
What could go wrong: This is a small, early-phase trial (64 participants) testing a combination of two existing drugs for a new purpose. The results may not be strong enough to change practice, and skin irritation from the creams is possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MELANOMA SKIN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

skin carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MELANOMA SKIN CANCER

Contacts and locations

Locations

Birmingham VA Medical Center

Birmingham, Alabama, 35233, United States
UAB Dermatology

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.